Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen

Abstract

Introduction Acetaminophen is a commonly used analgesic and antipyretic drug, and is frequently used to study gastric emptying. Due to its high permeability and high solubility, acetaminophen can be used as a pharmacologic model for medications with similar characteristics. The objective of this study was to assess the effect of liraglutide on the pharmacokinetics (PK) of acetaminophen in patients with type 2 diabetes. Methods This was a randomized, placebo-controlled, two-period crossover trial in which subjects with type 2 diabetes received placebo or liraglutide. After steady state PK of liraglutide 1.8 mg/ placebo were established, a single dose of acetaminophen 1 g was administered at the time of liraglutide C(max) (maximum concentration). The PK profile of acetaminophen was assessed at 18 time points during the 8-hour post-dosing period. Placebo and liraglutide were considered equivalent with respect to area under the curve (AUC)(0-∞) and AUC(0-480) min of acetaminophen if the 90% CI for the ratio was fully contained within the limits of 0.80 to 1.25. Results All subjects (n=18; mean [SD] age 59 [7] years, body mass index [BMI] 29.7 [4.2] kg/m(2), and glycated hemoglobin [HbA(1c)] 7.8% [0.6%]) completed the study. Equivalence was demonstrated between liraglutide 1.8 mg at steady state and placebo, with respect to acetaminophen AUC(0-∞) (estimated ratio 1.04; 90% CI: 0.97, 1.10) and acetaminophen AUC(0-480) min (estimated ratio 0.95; 90% CI: 0.89, 1.01). During liragluti…

Overview

Integrity signals

Registry

Crossref · 10.1007/s12325-011-0044-y

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 2

  1. Jonker D, Toft AD, Kristensen P, Knudsen LB, Watson E. Pharmacokinetic modelling of the oncedaily human glucagon-like peptide-1 analogue liraglutide in healthy volunteers and comparison to exenatide [abstract]. Diabetes. 2007;56(Suppl. 1):Abstract 160.
  2. Malm-Erjefält M, Ekblom M, Brøndsted L, Vouis J, Lennernäs H, Zdravkovic M. A randomised, doubleblind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects [abstract]. Diabetes. 2008;57(Suppl. 1):Abstract 130.

Cited by

See all 36

Metadata

Authors
Kapitza, C., Zdravkovic, M., Hindsberger, C., & Flint, A.
Affiliations
  • Profil Institute for Metabolic Research (DE)
  • Novo Nordisk (Denmark) (DK)
Corresponding author
Kapitza, Christoph
Venue
Advances in Therapy
Published
2011-07-20
Volume
28
Issue
8
Pages
650-660
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W2092305945
Cited by
36
References
32
Citations by year
2026: 1 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 2 · 2019: 5 · 2018: 1 · 2016: 2 · 2015: 4 · 2014: 4 · 2013: 3 · 2012: 3
FWCI
3.41
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Advances in Therapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
paracetamol, pharmacokinetics, drug-drug interactions, type 2 diabetes, gastric emptying, GLP-1 receptor agonists, food effect, Cmax, Tmax, bioequivalence, pharmacokinetic modeling, pharmacokinetic simulation, pharmacokinetic prediction
MeSH terms
Liraglutide, Acetaminophen, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Interactions, Gastric Emptying, Humans, Hypoglycemic Agents, Middle Aged, Cross-Over Studies, Analgesics, Non-Narcotic, Glucagon-Like Peptide 1, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. https://app.cochat.ai/papers/10.1007/s12325-011-0044-y
The paper
Kapitza, C., Zdravkovic, M., Hindsberger, C., & Flint, A. (2011). The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. Advances in Therapy. https://doi.org/10.1007/s12325-011-0044-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.